Lidocaine injection 2% (DrugBank: Lidocaine)
12 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
6 | パーキンソン病 | 0 |
13 | 多発性硬化症/視神経脊髄炎 | 0 |
34 | 神経線維腫症 | 0 |
46 | 悪性関節リウマチ | 0 |
51 | 全身性強皮症 | 0 |
70 | 広範脊柱管狭窄症 | 0 |
84 | サルコイドーシス | 0 |
86 | 肺動脈性肺高血圧症 | 0 |
168 | エーラス・ダンロス症候群 | 1 |
226 | 間質性膀胱炎(ハンナ型) | 0 |
231 | α1-アンチトリプシン欠乏症 | 0 |
256 | 筋型糖原病 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04036305 (ClinicalTrials.gov) | July 26, 2019 | 25/7/2019 | Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy Volunteers | Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy Volunteers | Ehlers-Danlos Syndrome;Anesthesia, Local | Drug: 0.9% Sodium Chloride Injection;Drug: Lidocaine Injection 2%;Drug: Bupivacaine Injection 0.5% | Vanderbilt University Medical Center | University of Calgary | Enrolling by invitation | 18 Years | N/A | All | 230 | United States |